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http://dx.doi.org/10.1016/j.kjms.201Abstract Management of skin avulsion with tissue exposure is a challenge for plastic surgeons.
Clinical observations have suggested that longer survival of skin flap prevents further contam-
ination and infection. Less well known is the role of atorvastatin in avulsion skin flap. Therefore,
we attempted to determine whether atorvastatin could alleviate avulsion skin flap in a rat
model. Twenty male SpragueeDawley rats were randomized into two groups: the atorvastatin
group and the control. Before operation, each rat received an initial blood perfusion scan as
baseline data. Then, each rat received an operation of skin flap incision, elevation, and resutur-
ing to the original position under general anesthesia. Another blood perfusion scan was per-
formed on each rat 30 minutes, 4 days, and 7 days postoperatively. On the 7th postoperative
day, the necrotic area of skin flap was measured as the skin flap viability. The skin flap tissues
at 2.5 and 5 cm distal to the skin flap base were collected for histopathological analysis, as well
as measurement of vascular endothelial growth factor (VEGF) mRNA expression, and vascular
density. Compared with 30 minutes postoperation, there was a significant increase in the ratio
of skin flap blood perfusion on the 4th and 7th days postoperation in both control and atorvas-
tatin groups (p< 0.05). Compared with the control group, there was a significant decrease in-
necrotic area, significant increase in ratio of skin flap blood perfusion on postoperation days 4
and 7, and significant increase in vascular density under high field at 2.5 cm distal to the base of
skin flap in the atorvastatin group (p< 0.05). The VEGF121 and VEGF165 mRNA expression at
2.5 cm distal to the base of skin flap differed significantly between the two groups (p< 0.05).
Compared with the control group, atorvastatin treatment improved skin flap blood perfusion,
vascular density, and necrotic area dependent on VEGF mRNA expression.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.t of Plastic Surgery, China Medical University Hospital and School of Medicine, China Medical
il.com (P.-K. Shih).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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elevated vertically with the base over the bilateral iliacSkin abrasion wounds over a large area are common.
Recovery of damaged skin over exposed tissue is beneficial
not only for further tissue growth but also reduces the risk
of infection. Various studies have addressed ischemic skin
flap survival. Vascular endothelial growth factor (VEGF; by
either pharmacological or gene facilitation) has shown
great viability and neovascularization over ischemic skin
flaps [1e3]. Other agents such as captopril (angiotensin-
converting enzyme inhibitor) [4], sildenafil (phosphodies-
terase inhibitors) [5], and aspirin have been demonstrated
to be beneficial for skin flap viability, although the detailed
mechanisms are still unclear.
Statins are drugs for treatment of hypercholesterolemia
which inhibit 3-hydroxy-3-methylglutaryl coenzyme A. In
addition to being a cholesterol-lowering class of drug, many
studies have suggested that statins are of benefit in the
prevention and treatment of various infections [6,7], as
well as in wound strengthening and healing [8,9], angio-
genesis [10e12], and apoptosis [13]. It was reported that
statins stimulated expression of several angiogenic media-
tors [VEGF, interleukin-8, angiopoietin (Ang)-1, Ang-2,
eNOS, and hemoxidase (HO)-1] in an ischemic hind limb
model [14]. Reports on the role of statins in preventing the
progression of ischemic skin flap are rare. Therefore, in this
study, we aimed to determine whether statins alleviated
the necrotic area and blood perfusion of the rat ischemic
skin flap and to examine the underlying mechanisms.
Materials and methods
Animals
All procedures were performed using SpragueeDawley rats
obtained from the National Science Council, and they were
approved by the Institutional Animal Care and Use
Committee of Kaohsiung Medical University.
Experimental groups
In this study, 20 SpragueeDawley (300e350 g) rats were
divided into two groups. All experimental rats were fed and
housed at Kaohsiung Medical University, following the
approved guidelines. All rats were handled as follows:
Control group (nZ 10): feed normal saline after surgery
by lavage for 7 days.
Atorvastatin group (nZ 10): feed atorvastatin after
surgery (10 mg/kg/day) by lavage for 7 days.
Atorvastatin (Lipitor; Abbott Co. Ltd., Chicago, IL, USA)
was purchased from Kaohsiung Medical University Hospital.
Surgical procedure
All surgical procedures were performed under Zoletil 50
anesthesia (Tiletamine and Zolazepam; Virbac Co. Ltd.,
Carros Cedex, France; 5 mg/kg, intraperitoneal injection).
Dorsal hair was shaved completely before operation. All
rats had caudally based McFarlane-type dorsal skin flaps
(3 10 cm) [15,16]. Along the designated area, the skinincluding the panniculus carnosus muscle was incised and
crest. To leave the skin flap with blood supply only from the
pedicle, an elastic sheet of the same area was placed below
the flap, and the flap was sutured with a 4e0 nylon suture
back to its original location.
Measurement of microcirculation in skin flap
To assess the changes in blood flow in the flap, the laser
Doppler imager (MoorLDI2-2l; Moor Instruments, Millwey,
UK) was used. Serial measurements of skin vascularity were
taken at four time points: before operation, and 30
minutes, 4 days, and 7 days after operation. The blood
perfusion change rate was expressed as percentage of value
obtained at 30 minutes, 4 days, or 7 days after operation/
value obtained before operation.
Evaluation of skin flap survival rate
The flap survival was evaluated on postoperative day 7. A
millimetric paper template was used to record the necrotic
area of each flap, and the necrotic area was calculated as
the percentage of necrotic area to the whole flap.
Tissue harvest
All rats were sacrificed on postoperative day 7. Skin
samples 2.5 and 5.0 cm distal to the base of the pedicle
were harvested and stored in liquid nitrogen and formalin
for further reverse transcription polymerase chain reaction
(RT-PCR) and histological assessment, respectively.
Measurement of VEGF mRNA expression
Total RNA was extracted from frozen skin sample with
TRIzol (Invitrogen) according to the manufacturer’s
instructions. Reverse transcription was preformed with
SuperScriptIII (Invitrogen) according to the manufacturer’s
instructions. Primers used for amplification of VEGF were as
follows: forward 50-TGC ACC CAC GAC AGA AGG GGA-30,
reverse 50-TCA CCG CCT TGG CTT GTC ACA T-30, GAPDH:
forward 50-GTA TGA CTC CAC TCA CGG CAA AT-30, reverse
50-GTA GAC TCC ACG ACA TAC TCA GCA C-30 [17]. The PCR
reaction for amplified VEGF and GAPDH was as follows:
95C for 5 minutes, and than 30 cycles of 95C for 15
seconds, 58C for 1 minute and 72C for 1 minute. The PCR
product was analyzed by electrophoresis using 1.5% agarose
gel; and the predicted lengths of the PCR products were
360 bp for VEGF121, 492 bp for VEGF165, 564 bp for VEGF189
and 152 bp for GAPDH, respectively.
Histopathological analysis
In each group, the harvested tissue was fixed in 10% buff-
ered formalin and 5-mm section was prepared from
paraffin-embedded tissues. Paraffin sections (5 mm thick)
were cut and stained with hematoxylineeosin (H&E) under
standard histological methods. Histopathological analysis
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groups.
Vascular density
Quantitative assessment of neovascularization was
executed under 400 magnification of the light micro-
scope. The number of vessels within the dermis level under
five random high power fields was calculated. An average
number of vessels of all fields represented vascular density.
Statistical analysis
The data were expressed as mean SD. Comparisons of
ratio of skin flap blood perfusion at different time points in
both control and Atorvastatin groups were determined by
one-way analysis of variance, followed by Tukey’s test for
post hoc comparisons. Comparisons of other parameters
between control and Atorvastatin groups were performed
by ManneWhitney test. A p value of less than 0.05 was
considered statistically significant. GraphPad Prism 5.0 was
used for all statistics.
Results
Effect of atorvastatin on viability of skin flap
The effect of atorvastatin on viability of skin flap is illus-
trated in Fig. 1. The percentages of necrotic area of
control and atorvastatin groups were 66.08 4.36% andFigure 1. Effect of atorvastatin on survival of skin flap on postop
the control and atorvastatin groups, respectively. Ratio of necrot
represents the mean ratio of necrotic area SD of the data pooled f
ratio of necrotic area between control and atorvastatin groups.43.83 13.12%, respectively. There was a significant
difference between the groups (p< 0.05). Fig. 1A and B
show the representative skin flap viability on post-
operative day 7 in control and atorvastatin-treated rats,
respectively.Effect of atorvastatin on blood perfusion of skin
flap
The effect of atorvastatin on blood perfusion of skin flap is
illustrated in Fig. 2. In the control group, the blood perfu-
sion ratios at 30 minutes, 4 days, and 7 days postoperation
were 0.273 0.067, 0.548 0.148, and 0.493 0.193,
respectively (Fig. 2B). There was a significant increase in
blood perfusion ratio on postoperative day 4 and day 7
compared with 30 minutes postoperation in the control
group (p< 0.05). Fig. 2A shows the representative blood
perfusion of skin flap in the control group before operation,
and 30 minutes, 4 days, and 7 days postoperation.
In the atorvastatin group, the blood perfusion ratios at
30 minutes, 4 days, and 7 days after operation were
0.477 0.208, 0.881 0.279, and 0.905 0.261, respec-
tively (Fig. 2D). There was a significant increase in blood
perfusion ratio on postoperative day 4 and day 7 compared
with 30 minutes after operation in the control group
(p< 0.05). Fig. 2A shows the representative blood perfusion
of skin flap in the atorvastatin group before operation, and
30 minutes, 4 days, and 7 days after operation.
Compared with the control group, there was a significant
increase in blood perfusion ratio in the atorvastatin group
on postoperative day 4 and day 7 (p< 0.05; Fig. 3).erative day 7. (A and B) Representative pictures of skin flap in
ic/original area in both groups is illustrated in (C). Each bar
rom each group (nZ 10). *p< 0.05, significant difference in the
Figure 2. Effect of atorvastatin on skin flap blood perfusion at different time points. (A and C) Representative images of skin flap
blood perfusions at different time points (Pre OP, Post OP þ30 minutes, þ4 days, and þ7 days) in control and atorvastatin groups,
respectively. (B and D) Ratios (Post OP/Pre OP) of blood perfusion in control (nZ 10) and atorvastatin groups (nZ 10), respec-
tively. Each bar represents the mean ratio of blood perfusion SD of the data pooled from each group. *p< 0.05, **p< 0.05,
significant difference in the ratio of blood perfusion between 30 minutes and 4 days postoperation or significant difference in the
ratio of blood perfusion between 30 minutes and 7 days postoperation, respectively.
Figure 3. Time course of ratio of skin flap blood perfusion
between two groups (nZ 10). *p< 0.05, significant difference
in the ratio of skin flap blood perfusion between control and
atorvastatin groups.
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The effect of atorvastatin on VEGF mRNA expression is
illustrated in Fig. 4. Fig. 4A and B show VEGF mRNA
expression at 2.5 and 5.0 cm distal to the base of the skin
flap, respectively. The ratio of VEGF121/GAPDH mRNA
expression at 2.5 cm distal to the base of the skin flap was
0.223 0.042 and 0.431 0.079 in control and atorvasta-
tin groups, respectively. The ratio of VEGF165/GAPDH
mRNA expression at 2.5 cm distal to the base of the skin
flap was 0.151 0.042 and 0.271 0.036 in control and
atorvastatin groups, respectively. The ratio of VEGF121/
GAPDH mRNA and VEGF165/GAPDH mRNA expression at
2.5 cm distal to the base of the skin flap showed a signifi-
cant difference between control and atorvastatin groups
(p< 0.05).
The ratio of VEGF121/GAPDH mRNA expression at 5.0 cm
distal to the base of the skin flap was 0.105 0.091 and
0.232 0.093 in control and atorvastatin groups, respec-
tively. The ratio of VEGF165/GAPDH mRNA expression at
5.0 cm distal to the base of the skin flap was 0.080 0.060
and 0.093 0.040 in control and atorvastatin groups,
respectively. The ratio of VEGF121/GAPDH mRNA and
VEGF165/GAPDH mRNA expression at 5.0 cm distal to the
base of the skin flap showed no significant difference
between control and atorvastatin groups.
Figure 4. Semiquantitative RT-PCR of VEGF121 and VEGF165 at 2.5 and 5.0 cm distal to the baseline of the skin flap on post-
operative day 7. (A) The RT-PCR of VEGF121 at 2.5 and 5.0 cm distal to the base of the skin flap in both control and atorvastatin
groups. (B) The RT-PCR of VEGF165 at 2.5 and 5.0 cm distal to the base of the skin flap in both control and atorvastatin groups. Each
bar represents the mean ratio of VEGF/GAPDH mRNA expression SD of the data pooled from each group (nZ 10). GAPDH was used
as internal control.
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flap
The effect of atorvastatin on vascular density of skin flap is
illustrated in Fig. 5. Fig. 5A and B show representative
histopathological pictures at 2.5 cm distal to the base of
the skin flap in control and atorvastatin-treated rats,
respectively. Fig. 5C and D show representative histopath-
ological pictures at 5.0 cm distal to the base of the skin flap
in control and atorvastatin-treated rats, respectively. The
average vascular density under high field at 2.5 cm distal to
the base of the skin flap was 1.5 1.12 and 3.86 0.82 in
control and atorvastatin groups, respectively (Fig. 5E).
There was a significant difference between groups at
2.5 cm distal to the base of the skin flap (p< 0.05). The
average vascular density under high field at 5.0 cm distal to
the base of the skin flap was 0.45 0.88 and 0.32 0.36 in
control and atorvastatin groups, respectively (Fig. 5F).
There was no significant difference between groups at
5.0 cm distal to the base of the skin flap (p> 0.05).
Discussion
Ischemic flap treated with VEGF gene therapy showed
improved ischemic flap survival and neoangiogenesis [1,2].
Agents such as sildenafil, celecoxib, and angiotensin-
converting enzyme inhibitor were proven to improve
ischemic flaps by induction of VEGF [4,5,18]. Some studies
have suggested that statins in different doses seem to
produce biphasic effects in angiogenesis. In their review
study, Hindler et al. [19] suggested that low doses of statins
facilitate tumor angiogenesis by stimulation of protein
kinase B and/or activation of endothelial nitric oxide syn-
thase, and high doses of statins inhibit angiogenesis by
inhibition of capillary tube formation and/or decreased
endothelial vascular growth factor release. In another
inflammation-related study, the angiogenesis was enhanced
with low-dose statin therapy (0.5 mg/kg/day) but wassignificantly inhibited with high concentrations of cer-
ivastatin or atorvastatin (2.5 mg/kg/day) [20]. The result of
our study suggested that atorvastatin (10 mg/kg/day)
improved flap necrotic area in rat skin flap models when
compared with the control group, but the dose in this study
could be considered high-dose statin therapy compared
with previous studies. However, one study suggested that
atorvastatin (10 mg/kg/day) strongly induced angiogenesis
in ischemic hind limbs [14]. Therefore, the definite
borderline of high/low dose of statins seems to have no
standard. More related studies are necessary.
The result of this study showed better blood perfusion of
ischemic skin flap on postoperative days 4 and 7 than 30
minutes after operation in both control and atorvastatin
groups. In a similar study presented by Lindenblat et al.
[21], capillary widening in the wound bed appeared at day 1
after grafting and increased until day 4. The maximum
expression of hypoxic-inducible factor-1a (HIF-1a)
appeared within the 1st 48 hours, but the peak of VEGF
expression occurred at 72 hours [21]. Multiple HIF-1 target
genes have been shown to modulate angiogenesis by
promoting the mitogenic and migratory activities of endo-
thelial cells [22]. Lindenblat et al.’s finding may explain
how the ischemic skin flap restored blood perfusion in the
animal model.
In Matsumura et al.’s [14] study, atorvastatin strongly
induced angiogenesis with increases in expressions of VEGF,
interleukin-8, Ang-1, Ang-2, eNOS, and HO-1 proteins in
ischemic hind limbs. Similar results were also proven in an
in vitro study, which suggested that atorvastatin stimulated
the expression of Ang-2, eNOS in human umbilical endo-
thelial cells [23]. The findings in our study showed that
atorvastatin significantly increased VEGF mRNA expression
on postoperative day 7 as compared with those without
treatments, which matched the finding of improved blood
perfusion and vascular density.
In Uygur et al.’s [24] study, tissue was harvested from 1,
3, and 5 cm distal to the base of the flap. We considered
that there should be no differences between control and
Figure 5. Effect of atorvastatin on vascular density of skin flap at different locations. Morphological changes of skin flap (H&E
staining, original magnification 10) are presented in (A)e(D). (A) 2.5 cm distal to the base of skin flap in atorvastatin group:
obviously patent vessels. (B) 2.5 cm distal to the base of skin flap in control group: patent vessels decreased compared with (A). (C)
5.0 cm distal to the base of skin flap in atorvastatin group: patent vessels obviously decreased compared with (A). (D) 5.0 cm distal
to the base of skin flap in control group: rare vessels available. Each arrow points to patent vessel. (E and F) Average vascular
densities under high field (magnification 40) in control (nZ 10) and atorvastatin group (nZ 10), respectively. Each bar represents
the mean average vascular density SD of the data pooled from each group. *p< 0.05, significant difference in average vascular
density between control and atorvastatin groups.
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which was the reason for our modification to tissue harvest
from 2.5 and 5 cm distal to the base of the flap.
There were some limitations in this study. One is that
the dose used was higher than that used in humans. No
study has found that the dose of atorvastatin (10 mg/kg/
day) is strongly associated with impaired liver function, but
studies have reported liver disease after atorvastatin
treatment [25]. In addition, although VEGF mRNA expres-
sion induction by statins is demonstrated in our study,
further time- and dose-dependent studies of statins are
desirable.
The flap necrotic area and blood perfusion in this study
were designed for gross observation of this flap. We found
that atorvastatin does decrease the necrotic area (avas-
cular zone) compared with the control group, as demon-
strated by the blood perfusion scan. However, the perfusion
scan showed non-homogenous distribution of vessel over all
flap. Therefore, we harvested tissue 2.5 and 5 cm distal tothe base of the flap to observe the vascular density and the
expression of VEGF mRNA. We found that there is no
difference between atorvastatin and control groups at 5 cm
distal to the base of the flap, but that there is significant
difference at 2.5 cm distal to the base of the flap. These
results suggested that the increased vascular density and
VEGF mRNA expression in proximal site of atorvastatin
group could supply more reliable flap area although no
differences were noted in vascular density and VEGF mRNA
expression in the control portion.
In conclusion, compared with the control group, ator-
vastatin improved skin flap blood perfusion, vascular
density, and necrotic area via VEGF-dependent pathway.
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